Cocrystal Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
COCP Nasdaq 2834 https://www.cocrystalpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cocrystal Pharma Inc

Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021 - Oct 14th, 2021 12:00 pm
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza - Oct 6th, 2021 12:49 pm
Here's Why We're Not Too Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation - Oct 1st, 2021 11:04 am
Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Sep 7th, 2021 12:00 pm
Cocrystal Pharma, Inc. (COCP) Reports Q2 Loss, Misses Revenue Estimates - Aug 16th, 2021 1:25 pm
Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates - Aug 16th, 2021 12:00 pm
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q2 Earnings? What You Should Know - Jul 29th, 2021 7:04 pm
Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants - Jul 29th, 2021 12:00 pm
Cocrystal Joins Russell Microcap® Index - Jun 28th, 2021 12:00 pm
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter - Jun 23rd, 2021 12:00 pm
Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19 - Jun 15th, 2021 4:03 pm
Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains - Jun 14th, 2021 1:48 pm
Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants - Jun 14th, 2021 12:30 pm
Cocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online - Jun 9th, 2021 6:30 pm
Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox - May 28th, 2021 12:00 pm
Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update - May 17th, 2021 12:00 pm
Cocrystal Pharma Announces Closing of $40 Million Bought Deal - May 7th, 2021 8:05 pm
Cocrystal Pharma Shares Plunge On $40M Equity Raise At 28% Discount - May 5th, 2021 10:37 am
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock - May 4th, 2021 10:41 pm
Cocrystal Doubles on Report of Progress on Covid Drugs - May 4th, 2021 1:05 pm